Retrospective analysis of oncologic outcome and quality of life following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC), based on a surgical database of the University Hospital Dresden, referring to the years 2013-2020

• Conditions: C48; Malignant neoplasm of retroperitoneum and peritoneum

• Registration Number: DRKS00028856
• Lead Sponsor: niversitätsklinikum Carl Gustav Carus

Brief Summary

Introduction It has been shown that cytoreductive surgery (CRS) in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) is an effective treatment for patients suffering from peritoneal malignancies. Despite good results, there is an ongoing debate about this treatment due to perioperative morbidity. The aim of this study is to identify relevant risk factors for an unfavorable postoperative outcome after CRS and HIPEC. Materials and methods A retrospective analysis of a prospectively recorded database of all patients undergoing CRS and HIPEC between 2013 and 2020 in the Department of Surgery of the University Hospital Dresden was performed with a special focus on certain surgical steps of multivisceral resection, one- or 2- stage CRS/HIPEC and underlying diagnosis as possible risk factors for worse postoperative course. Results N = 173 CRS and HIPEC procedures were performed for various diagnoses. Relevant postoperative morbidity was 24% and 30d-mortality 1.2%. Simultaneous liver resections, preoperative hypalbuminemia and 2-staged CRS/HIPEC were significant risk factors for a worse postoperative course in multivariable analysis. Assessment of the association of simultaneous anastomoses and morbidity and mortality was inconclusive. Conclusion CRS and HIPEC is a safe treatment without relevant intraoperative morbidity and mortality and acceptable postoperative outcome. One-stage CRS/HIPEC should be preferred.

Detailed Description

Not available

Study Timeline

• Study Completion: 2022-03-30
• Study Start: 2022-04-27
• Results First Posted: 2022-11-05
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 173

Inclusion Criteria

All patients who underwent cytoreductive surgery and/or HIPEC in the UKD (VTG) from 2013-2020 received cytoreductive surgery and/or HIPEC (regardless of underlying diagnosis).

Exclusion Criteria

does not apply

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Analysis and presentation of patient characteristics, perioperative and postoperative parameters as well as oncological parameters.

Secondary Outcome Measures

Name	Time	Method
- Univariate and multivariate analysis for the identification of risk factors for the occurrence of recurrence and long-term oncological outcome <br>- Subgroup analyses with respect to the underlying Tumor disease as well as the HIPEC regimen applied. <br>- Survey of the postoperative quality of life (QoL) by means of a a specific questionnaire.